News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
752,066 Results
Type
Article (76883)
Company Profile (362)
Press Release (674803)
Multimedia
Podcasts (164)
Webinars (26)
Section
Business (193303)
Career Advice (3297)
Deals (36203)
Drug Delivery (149)
Drug Development (86701)
Employer Resources (187)
FDA (17097)
Job Trends (15825)
News (343399)
Policy (35170)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2981)
Academic (1)
Accelerated approval (34)
Adcomms (36)
Allergies (147)
Alliances (49308)
ALS (181)
Alzheimer's disease (1790)
Antibody-drug conjugate (ADC) (345)
Approvals (17280)
Artificial intelligence (573)
Autoimmune disease (160)
Automation (37)
Bankruptcy (352)
Best Places to Work (12161)
BIOSECURE Act (22)
Biosimilars (203)
Biotechnology (240)
Bladder cancer (163)
Brain cancer (64)
Breast cancer (664)
Cancer (5034)
Cardiovascular disease (449)
Career advice (2814)
Career pathing (41)
CAR-T (306)
CDC (57)
Celiac Disease (2)
Cell therapy (803)
Cervical cancer (38)
Clinical research (73482)
Collaboration (1816)
Company closure (4)
Compensation (1174)
Complete response letters (73)
COVID-19 (2977)
CRISPR (96)
C-suite (877)
Cystic fibrosis (151)
Data (6321)
Decentralized trials (2)
Denatured (49)
Depression (151)
Diabetes (533)
Diagnostics (6947)
Digital health (45)
Diversity (13)
Diversity, equity & inclusion (44)
Drug discovery (264)
Drug pricing (223)
Drug shortages (36)
Duchenne muscular dystrophy (241)
Earnings (76843)
Editorial (65)
Employer branding (25)
Employer resources (163)
Events (110897)
Executive appointments (1025)
FDA (20280)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1545)
Gene editing (213)
Generative AI (50)
Gene therapy (659)
GLP-1 (1130)
Government (5264)
Grass and pollen (8)
Guidances (385)
Healthcare (20322)
HIV (61)
Huntington's disease (50)
IgA nephropathy (85)
Immunology and inflammation (295)
Immuno-oncology (61)
Indications (102)
Infectious disease (3261)
Inflammatory bowel disease (206)
Inflation Reduction Act (16)
Influenza (119)
Intellectual property (251)
Interviews (622)
IPO (17165)
IRA (59)
Job creations (4017)
Job search strategy (2292)
JPM (69)
Kidney cancer (16)
Labor market (83)
Layoffs (647)
Leadership (40)
Legal (8416)
Liver cancer (97)
Longevity (15)
Lung cancer (680)
Lymphoma (382)
Machine learning (44)
Management (64)
Manufacturing (837)
MASH (175)
Medical device (14427)
Medtech (14478)
Mergers & acquisitions (20163)
Metabolic disorders (1404)
Multiple sclerosis (166)
NASH (23)
Neurodegenerative disease (350)
Neuropsychiatric disorders (102)
Neuroscience (3112)
Neurotech (1)
NextGen: Class of 2026 (7291)
Non-profit (5012)
Now hiring (63)
Obesity (683)
Opinion (335)
Ovarian cancer (169)
Pain (216)
Pancreatic cancer (233)
Parkinson's disease (300)
Partnered (38)
Patents (509)
Patient recruitment (495)
Peanut (60)
People (59454)
Pharmaceutical (76)
Pharmacy benefit managers (33)
Phase 1 (22585)
Phase 2 (32023)
Phase 3 (24243)
Pipeline (5231)
Policy (331)
Postmarket research (3200)
Preclinical (9880)
Press Release (69)
Prostate cancer (245)
Psychedelics (57)
Radiopharmaceuticals (296)
Rare diseases (917)
Real estate (6272)
Recruiting (77)
Regulatory (26177)
Reports (50)
Research institute (2673)
Resumes & cover letters (523)
Rett syndrome (28)
RNA editing (19)
RSV (83)
Schizophrenia (160)
Series A (261)
Series B (197)
Service/supplier (16)
Sickle cell disease (103)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (3935)
State (2)
Stomach cancer (19)
Supply chain (112)
Tariffs (96)
The Weekly (113)
Vaccines (1136)
Venture capital (95)
Weight loss (469)
Women's health (90)
Worklife (22)
Date
Today (21)
Last 7 days (623)
Last 30 days (2062)
Last 365 days (31070)
2026 (2984)
2025 (31495)
2024 (36463)
2023 (41336)
2022 (52546)
2021 (57194)
2020 (56014)
2019 (49794)
2018 (37905)
2017 (34953)
2016 (34365)
2015 (39518)
2014 (31715)
2013 (30585)
2012 (29650)
2011 (29971)
2010 (28523)
Location
Africa (1063)
Alabama (85)
Alaska (7)
Arizona (257)
Arkansas (14)
Asia (45272)
Australia (8003)
California (11222)
Canada (3252)
China (1174)
Colorado (476)
Connecticut (481)
Delaware (340)
Europe (105774)
Florida (1679)
Georgia (349)
Hawaii (4)
Idaho (67)
Illinois (901)
India (67)
Indiana (522)
Iowa (22)
Japan (431)
Kansas (131)
Kentucky (39)
Louisiana (29)
Maine (72)
Maryland (1396)
Massachusetts (8131)
Michigan (330)
Minnesota (635)
Mississippi (6)
Missouri (139)
Montana (35)
Nebraska (27)
Nevada (127)
New Hampshire (85)
New Jersey (3012)
New Mexico (32)
New York (2992)
North Carolina (1565)
North Dakota (10)
Northern California (5450)
Ohio (347)
Oklahoma (23)
Oregon (44)
Pennsylvania (2279)
Puerto Rico (22)
Rhode Island (50)
South America (1407)
South Carolina (66)
South Dakota (1)
Southern California (4360)
Tennessee (171)
Texas (1786)
United States (40256)
Utah (335)
Vermont (1)
Virginia (276)
Washington D.C. (87)
Washington State (946)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
752,066 Results for "dong a st".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy
January 30, 2026
·
2 min read
Business
Shaperon and Dong-A ST Sign MOU for Nanobody-Based New Drug Development
Hudson Therapeutics announced that Shaperon, an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding with Dong-A ST for the development of nanobody-based new drugs.
June 10, 2024
·
4 min read
Press Releases
Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA
December 19, 2024
·
1 min read
Press Releases
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
January 29, 2026
·
3 min read
Press Releases
CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®
October 21, 2024
·
2 min read
FDA
US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®
October 11, 2024
·
1 min read
FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)
Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subsidiary of Intas Pharmaceuticals Ltd, in the United States has received a notification that the US Food and Drug Administration (“FDA”) has accepted its Biologics License Application (BLA) for DMB-3115, a proposed biosimilar to Stelara® (Ustekinumab), for substantive review.
January 5, 2024
·
2 min read
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar
Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara ® (Ustekinumab).
July 17, 2023
·
2 min read
Press Releases
Frédéric Prince to Succeed Christian Loss, Effective January 1st, 2026
January 5, 2026
·
1 min read
Press Releases
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to implant FDA-approved novel defibrillation lead
February 3, 2026
·
2 min read
1 of 75,207
Next
